CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.
Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F
The Marseille Cancer Research Center celebrates its 50th anniversary ! -
Our scientific priority is to tackle breast and colon metastatic cancers that are aggressive or resistant to treatments. This topic is addressed through four ambitious projects:
General workflow
To give the general direction to these projects, the team is headed by F Bertucci (pioneer in tumor profiling, medical oncologist and head of the translational research committee at the Paoli Calmettes Institute) and E Mamessier (Researcher at INSERM, cellular biologist, immunologist and expert at setting translational studies). This co-leadership allows to combine technical development and breaking new scientific topics with relevant clinical questions and access to patients’ samples.
The completion of each project is feasible thanks to the support of 18 additional people, each gifted in a specific discipline (bioinformatics, immunology, molecular biology, cellular biology, biochemistry…), so that they can work on most problematics, independently of the type of treatment.
In addition, the team is fully equipped with next generation sequencing (Nextseq500), pan-transcriptomic (Affymetrix), array-based comparative genomic hybridization (Agilent), circulating tumor DNA (BioRad) or Circulating tumor cells isolation (Parsortix and micromanipulator) platforms, and microfluidic devices (Ibidi, Fluigent, ..), Live Cell Imaging System, cell culture rooms dedicated to the processing of human samples…
Altogether, we develop precision medicine strategies based upon better classification of tumors, more therapeutic options, better targeting and better comprehension of the mechanisms of resistance to treatments.
Come and join us in this adventure !
All techniques/technologies used in the team are designed to fit with patients’ samples and to meet clinical needs: Profiling and classification of tumors, single cells resolution caomputational approaches, multiplexed-immunofluorescence from FFPE tissues, Patient tumor derived organoids (simple or complex co-cultures), liquid biopsies analysis, identification of new targets and design of new treatments.
OncoPredic’Team in June 2023
OncoPredic’Team at the LMDF charity run for patients
Team publications
Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F
Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S
de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, Birnbaum D, Mamessier E, Bertucci F
Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E
Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E
Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG
Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R
Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvière MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Gonçalves A, Foussat A, Chrétien AS, Olive D